Loading
The first US national count of breast cancer by receptor subtype, from 2010 when cancer registries began recording HER2: 12.2 percent of cases were triple-negative, and Black women had the highest rate of that subtype.
Howlader, Altekruse, Li, Chen and colleagues assessed breast cancer subtypes defined by joint hormone receptor and HER2 status across the 28 percent of the US population covered by SEER registries, which began collecting HER2 in 2010, with age-specific rates for non-Hispanic white, non-Hispanic Black, non-Hispanic Asian Pacific Islander and Hispanic women and polytomous logistic regression on age, ethnicity, county poverty, registry, stage, grade, size and nodes. Among cases with known status, 36,810 (72.7 percent) were hormone receptor-positive/HER2-negative, 6,193 (12.2 percent) triple-negative, 5,240 (10.3 percent) hormone receptor-positive/HER2-positive and 2,328 (4.6 percent) hormone receptor-negative/HER2-positive; 6,912 (12 percent) were unknown. Non-Hispanic Black women had the highest triple-negative incidence; triple-negative patients were more likely to be non-Hispanic Black and Hispanic, 10 to 30 percent less likely to be diagnosed at older ages, and 6.4- to 20-fold more likely to present with high-grade disease.
The denominator for US triple-negative disparity statistics and the origin of the 10 to 15 percent figure quoted for the subtype's share of breast cancer.
Shares Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, National Cancer Institute (NIH), HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares JNCI: Journal of the National Cancer Institute, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.